EFFECTIVENESS AND COST OF INTEGRATING A PROTOCOL WITH USE OF LIRAGLUTIDE 3.0 MG INTO AN OBESITY SERVICE: (STRIVE Study)
Phase of Trial: Phase IV
Latest Information Update: 25 Jun 2018
At a glance
- Drugs Liraglutide (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Acronyms STRIVE
- 31 Aug 2018 Biomarkers information updated
- 14 Jun 2018 Planned number of patients changed from 400 to 375.
- 14 Jun 2018 Status changed from withdrawn prior to enrolment to recruiting.